1. Abe I, Sato S, Honi K, Suzuki M, Sato H (1982) Role of dephosphorylation in accumulation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity. Cancer Res 42: 2846–2851
2. Andreeff M, Tafuri A, Hegewisch-Becker S (1990) Colony-stimulating factors (rh G-CSF, rh GM-CSF, rh IL 3, and BCGF) recruit myeloblastic and lymphoblastic leukemic cells and enhance the cytotoxic effects of cytosine-arabinoside. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute leukemias — prognostic factors and treatment strategies. II. Springer, Berlin Heidelberg New York, pp 747–762
3. Baguley BC, Falkenhaug EM (1971) Plasma half-life of cytosine arabinoside (NSC-63878) in patients treated for acute myeloblastic leukemia. Cancer Chemother Rep 55: 291–298
4. Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCredie K (1981) In vivo cellular kinetic and pharmacological studies of 1-β-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 41: 1227–1235
5. Bhalla K, Nayak R, Grant S (1984) Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D-arabinofuranosylcytosine. Cancer Res 44: 5020–5037